4Combes B, Shorey J, Barrera A, et al. Glomerulonephritis with deposition of Australia antigen antibody complexes in glomerular base-ment memberane[ J]. Lancet, 1971, 2(7718 ) : 234.
5Lai KN, Lai FM, TamJ S, et al. IgA nephropathy associated with Chronic hepatitis B Virus infection in adults: the pathogenetic ole of HBsAg[ J]. Pathol, 1989,157 (4) : 321.
6Lai KN, Lai FM, Tam TS, et al. Strong association Between IgA Nephropathy and hepatitis B surface antigenemia in endemic areas[ J]. CLin Nephrol, 1988,29: 229.
7Bhimma R, Coovadia HM. Hepatitis B Virus associated nephropathy[ J]. Am J Nephrol, 2004, 24(2): 198 -211.
8Taskapan H, Oymak O, Dogukan A, et al. Transformation of hepatitis B virus - related membraneous glomerulonephritis to crescentic form [ J ]. Clin Nephrol, 2000,54 ( 2 ) : 161 - 163.
9Seifer M, Hamatake RK, Colomo R J, et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS - 200475 and lobucavir[ J]. Antimicrob Agents Chemother, 1998, 42 (12) : 3200 - 3203.
10Ulim F. New Insight on hepatitis B Virus persistence from the study of intrahepatic viral cccDNA [ J ]. Hepatol, 2005,42:302 - 308.
7Vecnstra DL, Sullivan SD,Clarke L,et a l. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B [J]. Pharmacoeconomics, 2007, 25 (11 ) : 963- 977.
9KUSAKABE A,TANAKA KURBANOV F. Virologicalfeatures of hepatitis b virus-associated nephropathy injapan[j]. J Med Virol,2007,79(9): 1 305-1 311.
10MARCELLIN P, CHANG T-T, LIM SGL, et al.Long-term efficacy and safety of adefovir dipivoxil for the treatment HBeAg-positive chronic hepatitis B [J] .Hepatol, 2008, 48 (3) : 750-758.
